Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy

Trial Profile

Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke; Thrombosis
  • Focus Adverse reactions
  • Acronyms RE-CIRCUIT
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 19 Mar 2017 Primary endpoint of incidence of Major Bleeding Events has been met, according to results published in the New England Journal of Medicine.
    • 19 Mar 2017 Results published in the New England Journal of Medicine
    • 19 Mar 2017 Results from this trial were presented at the American College of Cardiology (ACC) Congress 2017 and published simultaneously in the New England Journal of Medicine (NEJM), according to a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top